Gilles Wandeler - Infectious Diseases

Author Information

Gilles Wandeler is a prominent researcher in the field of Infectious Diseases, currently affiliated with the Department of Infectious Diseases at Bern University Hospital and the University of Bern in Switzerland. Additionally, he is associated with the Institute of Social and Preventive Medicine at the University of Bern. His research primarily focuses on chronic infectious diseases, particularly the intersection of viral infections such as HIV, Hepatitis B, and Hepatitis C, reflecting his interest in both clinical outcomes and public health implications.

Research Contributions

Gilles Wandeler has significantly contributed to understanding infectious diseases, with a strong emphasis on viral co-infections and their management. His work includes the diagnostic performance of fibrosis markers for chronic Hepatitis B in sub-Saharan Africa, evaluation of HIV drug resistance, and the pharmacokinetics of antiretroviral therapies. He has also explored weight and metabolic changes in individuals living with HIV and conducted studies on Hepatitis screening and care. His research is not only crucial for advancing clinical practices but also in shaping public health policies, especially in regions with high burdens of viral infections.

Aliases

Gilles Wandeler is also known by several aliases in academic publications, including G Wandeler and G. Wandeler. These variations are often used interchangeably across different research papers and citations.

Publication and Citation Metrics

Metric	Value
Citation Count	6021
H-index	34
Paper Count	233

Publications:

Diagnostic performance of non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa: a Bayesian individual patient data meta-analysis

DOI: 10.1101/2022.03.18.22272415

Year: 2022

Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.

DOI: 10.1016/j.jclinepi.2022.02.005

Year: 2022

An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters

DOI: 10.3390/v14040784

Year: 2022

Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir‐based regimens in SIMPL'HIV clinical trial

DOI: 10.1111/bcp.14832

Year: 2021

Screening for Hepatocellular Carcinoma among adults with HIV/Hepatitis B coinfection in Zambia: A Pilot Study

DOI: 10.1016/j.ijid.2021.12.338

Year: 2021

Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV

DOI: 10.7326/M20-4853

Year: 2021

Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study

DOI: 10.21203/rs.3.rs-1065495/v1

Year: 2021

The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences

DOI: 10.1097/QAD.0000000000003112

Year: 2021

Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal

DOI: 10.1111/jvh.13615

Year: 2021

An approach to quantifying the interaction between behavioural and transmission clusters: the case of Hepatitis C virus infections in HIV positive men who have sex with men

DOI: 10.1101/2021.08.22.21261697

Year: 2021

What are Host-Pathogen Interactions?

When Should Antivirals Be Administered?

What are the Recent Advances in Serological Testing?

What are the Symptoms of Herpes?

What Diseases Does DTaP Protect Against?

Can Targeting Metabolic Pathways Serve as a Therapeutic Strategy?

What diseases does it cause?

How Do Pathogens Exploit Host Metabolic Pathways?

Why is Antimicrobial Resistance a Concern?

What is Plasmodium?

Partnered Content Networks

Relevant Topics